Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents.
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. Am J Cardiol. 2001 Feb 16; 87(4A):1A-7A.